Ischemic events after successful thrombolysis have been reported to occur in 18-32% of patients treated for acute myocardial infarction with thrombolytic therapy, and previous studies in which patients received streptokinase suggest that risk of early recurrent ischemia is closely related to the presence of a high-grade residual stenosis. If these events are predictable after intravenous recombinant tissue-plasminogen activator (rt-PA) thrombolytic therapy, then further intervention after its use could be targeted at selected patients. One-hundred ninety-two patients from the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) I and TAMI III trials had successful rt-PA-mediated thrombolysis without immediate coronary angioplasty (PTCA). One-hundred seventy-four of these patients (92%) had prehospital discharge angiography. The mean age was 56±11 years; 81% were men; the infarct-related artery was the left anterior descending in 76 (39.8%), the left circumflex in 24 (12.6%), and the right coronary artery in 91 (47.6%). Thrombolysis with rt-PA resulted in a residual 73±13% diameter and 0.95+±0.51 mm stenosis by quantitative coronary arteriography, and Thrombolysis in Myocardial Infarction (TIMI) flow grade 2 in 59.2% and 3 in 40.8% of stenoses as assessed on angiograms obtained 90 minutes after the initiation of rt-PA therapy. Recurrent ischemic events (ischemia requiring emergency percutaneous transluminal coronary angioplasty or urgent bypass surgery, reocclusion of the infarct-related artery, or cardiac death) occurred in 41 patients (21.3%). The recurrent ischemic events were not related to any of eight prospectively defined variables: the infarct-related artery, TIMI flow grade, percent diameter stenosis, absolute luminal diameter, angiographically-defined thrombus, diffuse disease or ectasia in the infarct-related artery, or Ambrose morphology of the infarct-related stenosis. Thus, 1) recurrent ischemic events are frequent after rt-PA and 2) such events are not predictable by findings available by in-depth quantitative and morphologic assessment at the time of angiography performed 90 minutes after rt-PA administration. It follows with the inability to stratify a patient's risk of recurrent ischemia that the decision for triage to coronary revascularization procedures after successful thrombolysis with rt-PA remains an especially difficult one. (Circulation 1989;80:1159-1165 E arly recurrent ischemic events occur in 18-32% of patients treated for acute myocardial infarction with successful thrombolytic therapy.'-6 The ability to predict which patients are likely to have such events would have a profound impact on triage to definitive coronary revascularization procedures. Reports from series of patients
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Methods
Origin and Initial Treatment of Patients All patients from the TAMI I and III studies6,7 who had Thrombolysis in Myocardial Infarction (TIMI) flow grade equal to or more than 28 on angiograms performed 90 minutes after the administration of intravenous rt-PA, who did not have immediate coronary angioplasty, and who had follow-up angiography or cardiac death before hospital discharge were eligible for this analysis. The criteria for patient entry into the TAMI I and III studies has been previously described,6,7 but briefly, patients had to have less than 4-6 hours of chest pain and electrocardiographic ST-segment elevation equal to or more than 1 mm in two or more contiguous leads and were excluded if they were considered to be at high risk of bleeding with intravenous thrombolytic therapy.
Patients in TAMI I received intravenous singlechain tissue-plasminogen activator (Genentech, South San Francisco, California), 60 mg the first hour, 20 mg during the second and third hours, and 10 mg for each of the last 5 hours, or 1 mg/kg body wt in the first hour and the remaining amount (of a total of 150 mg) given in equal amounts per hour in a 5-hour maintenance infusion.6 Patients in TAMI III received 135-150 mg of intravenous rt-PA over 6 hours, administered in a manner similar to the second dosing schedule for TAMI I. During cardiac catheterization, patients in TAMI I received 5,000 units intravenous heparin.
Patients in TAMI III were randomized to receive 10,000 units heparin at the time of initial rt-PA administration or immediately after the 90 minute angiogram. Patients in TAMI 1110 were not included in this study because they received combination rt-PA and urokinase in varying doses.
Postreperfusion Therapy and Follow-up
After cardiac catheterization, patients in both TAMI I and III received 500-1,000 units/hr intravenous heparin, adjusted to maintain the partial thromboplastin time at 1.5-2 times control. Patients also received 325 mg aspirin daily and 30-60 mg diltiazem orally four times a day.
The protocol for both trials required that patients who had recurrence of more than 20 minutes of angina that was not responsive to nitrates and was accompanied by electrocardiographic ST-segment changes be returned to the cardiac catheterization laboratory and considered for emergency angioplasty or bypass surgery. At 7-10 days, cardiac catheterization was performed on all patients who provided informed consent to determine the patency of the infarct-related artery.
Recurrent ischemic events were defined as any of the following that had occurred before hospital discharge: 1) emergency angioplasty for recurrent ischemia judged to be from the infarct artery; 2) urgent bypass surgery for ischemia from the infarct artery; 3) reocclusion, defined as recurrent total occlusion (TIMI flow grade 0 or 1) of the infarctrelated artery, without attempted angioplasty or bypass surgery; or 4) cardiac death.
Angiographic Core Laboratory
All cineangiograms were forwarded to the TAMI Angiographic Core Laboratory for analysis. This included measurement of the 90-minute post-rt-PA residual stenosis with use of an automated edgedetection computer algorithm,11 evaluation of the flow pattern of the infarct-related artery (TIMI flow grades 0-3, with grade 2 further subdivided as follows: 2A, delayed filling of the infarct-related artery with completion of filling by five cardiac cycles after contrast injection; 2B, delayed infarctartery filling with completion of filling achieved after five cardiac cycles; and 2C, delayed filling of the infarct-related artery with markedly prolonged washout that, if present, took scoring priority over 2A, 2B, or 3), and scoring of the infarct-related stenosis for prospectively defined morphologic characteristics (Table 4) The following other patient variables were also recorded but were not formally tested as correlates of the clinical end point: age, gender, diabetes, history of smoking, hypertension, hypercholesteremia, heart rate, and blood pressure on presentation to the cardiac catheterization laboratory, stenosis calcification, stenosis associated with a branch point, stenosis associated with a bend point,13 stenosis length (mm), collateral vessels beyond the stenosis, intermittent artery patency in the cardiac catheterization laboratory, use of aspirin at home before hospital admission, and the administration of aspirin in the cardiac catheterization laboratory. Patients with "silent" reocclusion were considered to have had their reocclusion at the time of its angiographic documentation.
Results

Patient and Stenosis Characteristics
Selected patient and infarct-related artery characteristics are described in Tables 1 and 2, and for both groups in TAMI 3.7 Third, the inability to determine whether recurrent ischemia contributed to the death of the four patients who died without catheterization immediately before death slightly lessens the power of the study. Nonetheless, the results were unchanged whether these patients were considered to have recurrent ischemia or if they were excluded from the analysis. Fourth, an accurate assessment of the importance of therapeutic heparinization on likelihood of recurrent ischemia could not be made because the duration and extent of anticoagulation were not coded in TAMI I patients. Finally, these results were obtained in patients receiving a somewhat larger dose of rt-PA than is currently recom- 
